Yusuke Kiyoura
Overview
Explore the profile of Yusuke Kiyoura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akaho R, Kiyoura Y, Tamai R
J Oral Biosci
. 2024 Apr;
66(2):412-419.
PMID: 38614429
Objectives: Toll-like receptors (TLRs) recognize whole cells or components of microorganisms. Alendronate (ALN) is an anti-bone-resorptive drug that has inflammatory side effects. The aim in this study was to examine...
2.
Alendronate augments lipid A‑induced IL‑1β release by ASC‑deficient RAW264 cells via AP‑1 activation
Watanabe N, Tamai R, Kiyoura Y
Exp Ther Med
. 2023 Nov;
26(6):577.
PMID: 38023354
Alendronate (ALN) is an anti-bone-resorptive drug with inflammatory side effects. ALN upregulates lipid A-induced interleukin (IL)-1α and IL-1β release by J774.1 cells via apoptosis-associated speck-like protein containing a caspase recruitment...
3.
Mashima I, Liao Y, Lin C, Nakazawa F, Haase E, Kiyoura Y, et al.
Microorganisms
. 2021 Aug;
9(8).
PMID: 34442854
The genus is a common and abundant member of the oral microbiome. It includes eight species, , , , , , , and . They possess important metabolic pathways that...
4.
Tamai R, Mashima I, Kiyoura Y
Inflammation
. 2021 Jun;
44(5):2132-2141.
PMID: 34080091
Nitrogen-containing bisphosphonates (NBPs), such as alendronate (ALN), are anti-bone-resorptive drugs that have inflammatory side effects. We previously reported that ALN augmented lipid A-induced interleukin (IL)-1β production and NOD-like receptor pyrin...
5.
Mashima I, Nakazawa F, Tamai R, Kiyoura Y
Microbiol Resour Announc
. 2021 Apr;
10(17).
PMID: 33927042
We report the complete genome sequence of JCM 33966 (=CCUG 74597). This bacterium is a member of the oral and has the potential to be anticariogenic as an oral probiotic...
6.
Mashima I, Theodorea C, Djais A, Kunihiro T, Kawamura Y, Otomo M, et al.
Int J Syst Evol Microbiol
. 2020 Dec;
71(1).
PMID: 33263509
Two strains of previously unknown Gram-negative cocci, T1-7 and S6-16, were isolated from the oral cavity of healthy Japanese children. The two strains showed atypical phenotypic characteristics of members of...
7.
Yambe N, Tamai R, Mashima I, Kiyoura Y
Immunopharmacol Immunotoxicol
. 2020 Nov;
43(1):51-57.
PMID: 33251898
Objective: Pretreatment of J774.1 cells with etidronate, a non-nitrogen-containing bisphosphonate (non-NBP) used as an antibone resorptive drug, was previously reported to inhibit Toll-like receptor (TLR) 2 agonist-induced proinflammatory cytokine production....
8.
Kobayashi-Sakamoto M, Maeda T, Yusa J, Kato Y, Kiyoura Y
Microb Pathog
. 2020 Jun;
149:104285.
PMID: 32585292
Osteoprotegerin (OPG) prevents binding of receptor activator of nuclear factor-kappa B ligand (RANKL) to RANK. Recent studies have reported that immune cell RANK-RANKL interactions are critical to the infection process....
9.
Tamai R, Suzuki K, Mashima I, Kiyoura Y
Int Immunopharmacol
. 2020 Jan;
79:106085.
PMID: 31901621
MPMBP is a novel non-nitrogen-containing bisphosphonate (non-NBP) which possesses anti-bone resorptive activity and an antioxidant side chain. This study aimed to assess the effects of MPMBP on the production of...
10.
Tamai R, Kiyoura Y
Folia Microbiol (Praha)
. 2019 Jan;
64(4):555-566.
PMID: 30656591
Candida albicans can enhance the invasion of oral epithelial cells by Porphyromonas gingivalis, although the fungus is not a periodontal pathogen. In this study, we investigated whether C. albicans augments...